LU90752I2 - Panretin-alitretinoin et ses d-riv-s pharmaceutiquement acceptables - Google Patents

Panretin-alitretinoin et ses d-riv-s pharmaceutiquement acceptables

Info

Publication number: LU90752I2
Authority: LU; Luxembourg
Prior art keywords: ligands; retinoid; retinoic acid; present; panretin
Prior art date: 1991-12-18

Application number

LU90752C

Other languages

English (en)

Original Assignee

Salk Inst For Biological Studi

Baylor College Medicine

Ligand Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-12-18

Filing date

2001-04-04

Publication date

2001-06-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25202656&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU90752(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-04-04 Application filed by Salk Inst For Biological Studi, Baylor College Medicine, Ligand Pharm Inc filed Critical Salk Inst For Biological Studi

2001-06-05 Publication of LU90752I2 publication Critical patent/LU90752I2/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/20—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by carboxyl groups or halides, anhydrides, or (thio)esters thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/26—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing rings other than six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/46—Unsaturated compounds containing hydroxy or O-metal groups containing rings other than six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/80—Unsaturated compounds containing keto groups containing rings other than six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
- C12P7/04—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Zoology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Wood Science & Technology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Cell Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Obesity (AREA)
Physics & Mathematics (AREA)
High Energy & Nuclear Physics (AREA)
Diabetes (AREA)
Immunology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Dermatology (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

LU90752C 1991-12-18 2001-04-04 Panretin-alitretinoin et ses d-riv-s pharmaceutiquement acceptables LU90752I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US80998091A	1991-12-18	1991-12-18
PCT/US1992/011214 WO1993011755A1 (fr)	1991-12-18	1992-12-18	Procedes permettant la modulation de processus utilisant des recepteurs de retinoides comme mediateurs et composes utiles dans ce contexte

Publications (1)

Publication Number	Publication Date
LU90752I2 true LU90752I2 (fr)	2001-06-05

Family

ID=25202656

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU90752C LU90752I2 (fr)	1991-12-18	2001-04-04	Panretin-alitretinoin et ses d-riv-s pharmaceutiquement acceptables

Country Status (11)

Country	Link
EP (2)	EP0807624B1 (fr)
JP (2)	JP4001618B2 (fr)
AT (2)	ATE439341T1 (fr)
AU (1)	AU679171B2 (fr)
CA (1)	CA2123223C (fr)
DE (4)	DE10199015I2 (fr)
DK (1)	DK0617614T3 (fr)
ES (1)	ES2066750T3 (fr)
LU (1)	LU90752I2 (fr)
NL (1)	NL300043I2 (fr)
WO (1)	WO1993011755A1 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5968989A (en)	1991-12-18	1999-10-19	The Salk Institute For Biological Studies	Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
US7056954B2 (en)	1991-12-18	2006-06-06	The Salk Institute For Biological Studies	Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
CZ282548B6 (cs) *	1992-01-22	1997-08-13	F. Hoffmann-La Roche Ag	Farmaceutický přípravek
US5962731A (en) *	1992-04-22	1999-10-05	Ligand Pharmaceuticals Incorporated	Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US5780676A (en) *	1992-04-22	1998-07-14	Ligand Pharmaceuticals Incorporated	Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
US5466861A (en) *	1992-11-25	1995-11-14	Sri International	Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
EP0678087B1 (fr) *	1993-01-11	1999-03-17	Ligand Pharmaceuticals, Inc.	Composes a activite selective pour les recepteurs du retinoide x, et systeme de modulation des processus utilisant des recepteurs du retinoide x comme mediateurs
US5399586A (en) *	1993-03-11	1995-03-21	Allergan, Inc.	Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
US5585244A (en) *	1994-06-10	1996-12-17	Ligand Pharmaceuticals Incorporated	Detection of retinoid X receptor subtype γ proteins
CA2211142A1 (fr) *	1995-01-23	1996-08-01	Ligand Pharmaceuticals Incorporated	Recepteur .gamma. de retinoide x humain (hrxr-gamma)
US6942980B1 (en)	1995-09-01	2005-09-13	Allergan, Inc.	Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
WO1997010813A1 (fr)	1995-09-18	1997-03-27	Ligand Pharmaceuticals Incorporated	Antagonistes de ppar gamma pour le traitement de l'obesite
US5741896A (en)	1996-06-21	1998-04-21	Allergan	O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5728846A (en)	1996-12-12	1998-03-17	Allergan	Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
US5998654A (en) *	1997-07-25	1999-12-07	Ligand Pharmaceuticals Incorporated	Retinoic acid receptor antagonist compounds and methods
WO1999063980A1 (fr)	1998-06-12	1999-12-16	Ligand Pharmaceuticals Inc.	Traitement du cancer du sein resistant aux anti-oestrogenes avec des modulateurs de rxr
US6147224A (en) *	1998-10-01	2000-11-14	Allergan Sales, Inc.	2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
US6403638B1 (en)	1998-10-01	2002-06-11	Allergan Sales, Inc.	2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
US6048873A (en) *	1998-10-01	2000-04-11	Allergan Sales, Inc.	Tetrahdroquinolin-2-one 6 or 7-yl, tetrahdroquinilin-2-thione 6 or 7-yl pentadienoic acid and related derivatives having retinoid-like biological activity
FR2787789B1 (fr) *	1998-12-29	2002-06-14	Lipha	Benzopyranes et benzoxepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparations
WO2000061232A2 (fr)	1999-04-14	2000-10-19	Allergan Sales, Inc.	Methodes et compositions destinees au traitement et a la prevention de maladies pulmonaires
AU4228000A (en)	1999-04-14	2000-11-14	Allergan Sales, Inc.	Methods and compositions for the treatment and prevention of lung disease
US6177588B1 (en)	1999-05-07	2001-01-23	Allergan Sales, Inc.	1-alkoxy and 1-acyloxy substituted cyclohex-1-ene compounds and sulfur and 1-alkoxycarbonyl analogs having retinoid-like biological activity
US6166244A (en)	1999-05-07	2000-12-26	Allergan Sales, Inc.	Oxygen, sulfur and nitrogen substituted cyclohexene and cyclohexane derivatives having retinoid-like biological activity
US6127382A (en) *	1999-08-16	2000-10-03	Allergan Sales, Inc.	Amines substituted with a tetrahydroquinolinyl group an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
US6093838A (en) *	1999-08-16	2000-07-25	Allergan Sales, Inc.	Amines substituted with a dihydro-benzofuranyl or with a dihydro-isobenzofuranyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
US6313168B1 (en)	1999-12-15	2001-11-06	Allergan Sales, Inc.	Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
DK1741446T3 (da)	2000-01-21	2008-06-02	Novartis Pharma Ag	Kombinationer indeholdende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler
US6613917B1 (en)	2000-03-23	2003-09-02	Allergan, Inc.	Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
TWI281911B (en) *	2000-04-04	2007-06-01	Allergan Inc	Treatment of tumors with RARalpha selective retinoid compounds in combination with other anti-tumor agents
US6313107B1 (en)	2000-08-29	2001-11-06	Allergan Sales, Inc.	Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
US6380256B1 (en)	2000-08-29	2002-04-30	Allergan Sales, Inc.	Compounds having activity as inhibitors of cytochrome P450RAI
US6369225B1 (en)	2000-08-29	2002-04-09	Allergan Sales, Inc.	Compounds having activity as inhibitors of cytochrome P450RAI
US6387951B1 (en)	2000-08-29	2002-05-14	Allergan Sales, Inc.	Compounds having activity as inhibitors of cytochrome P450RAI
US6252090B1 (en)	2000-08-29	2001-06-26	Allergan Sales, Inc.	Compounds having activity as inhibitors of cytochrome P450RAI
US6740676B2 (en)	2002-03-19	2004-05-25	Allergan, Inc.	4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-benzoic and 2-[4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-phenyl]-acetic acid, their esters and salts having cytochrome p450rai inhibitory activity
US6720423B2 (en)	2002-04-30	2004-04-13	Allergan, Inc.	Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
US6620963B1 (en)	2002-09-19	2003-09-16	Allergan, Inc.	TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-PHENYL AND TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-HETEROARYL AND RELATED COMPOUNDS HAVING RARα RECEPTOR SELECTIVE BIOLOGICAL ACTIVITY
US6759547B1 (en)	2003-01-14	2004-07-06	Allergan, Inc.	5,6,7,8-tetrahydronaphthalen-2-yl 2,6-difluoroheptatrienoic acid derivatives having serum glucose reducing activity
US7019034B2 (en)	2003-01-28	2006-03-28	Allergan, Inc.	Compositions and methods for reducing serum glucose and triglyceride levels in diabetic mammals
US6759546B1 (en)	2003-02-04	2004-07-06	Allergan, Inc.	3,5-di-iso-propyl-heptatrienoic acid derivatives having serum glucose reducing activity
US6884820B2 (en)	2003-04-03	2005-04-26	Allergan, Inc.	5,6,7,8-tetrahydronaphthalen-2-yl-7-fluoroalkyl-heptatrienoic acid derivatives having serum glucose reducing activity
US6734193B1 (en)	2003-06-03	2004-05-11	Allergan, Inc.	(1,2,3,4-tetrahydroquinolin-8-yl)-heptatrienoic acid derivatives having serum glucose reducing activity
US6936636B2 (en)	2003-06-26	2005-08-30	Allergan, Inc.	5-[phenyl-tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl-cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activity
US6887896B1 (en)	2003-10-29	2005-05-03	Allergan, Inc.	7-[(7-Alkoxy)-chrom-3-en-6-yl]-heptatrienoic acid and 7-[(3-alkoxy)-5,6-dihydronaphthalen-2-yl]-heptatrienoic acid derivatives having serum glucose reducing activity
JP2007518719A (ja)	2003-12-26	2007-07-12	アラーガン　インコーポレイテッド	ＲＡＲγレチノイド受容体アンタゴニスト活性を有する二置換カルコンオキシム
US7476673B2 (en)	2003-12-30	2009-01-13	Allergan, Inc.	Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors
US20160263189A1 (en)	2013-10-23	2016-09-15	Acadia Pharmaceuticals Inc.	Treatment of a neurodegenerative disease or disorder
WO2020112889A2 (fr)	2018-11-26	2020-06-04	Denali Therapeutics Inc.	Procédés de traitement du métabolisme lipidique dérégulé

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS62215581A (ja) *	1986-03-18	1987-09-22	Koichi Shiyudo	フラボンカルボン酸誘導体
US4885311A (en) *	1987-06-29	1989-12-05	Molecular Design International	Topical transretinoids for treatment of acne and skin diseases
LU86969A1 (fr)	1987-08-12	1989-03-08	Oreal	Association de derives de pyrimidine et de retinoides en composants separes pour induire et stimuler la croissance des cheveux et diminuer leur chute
US4916250A (en) *	1988-10-31	1990-04-10	Loyola University Of Chicago	Phosphonate reagent compositions
FR2641184B1 (fr)	1988-12-30	1991-04-05	Oreal	Composition pour induire et stimuler la croissance des cheveux et/ou freiner leur chute, a base de derives de pyrimidine et de filtres solaires
ES2022025A6 (es) *	1990-05-07	1991-11-16	Univ Valencia Estudi General	Procedimiento para la preparacion de acidos retinoicos y sus derivados.
JP2948923B2 (ja) *	1990-12-27	1999-09-13	日清製粉株式会社	レチノイン酸およびその異性体の製造方法
CZ282548B6 (cs)	1992-01-22	1997-08-13	F. Hoffmann-La Roche Ag	Farmaceutický přípravek

1992
- 1992-12-18 AU AU34218/93A patent/AU679171B2/en not_active Expired
- 1992-12-18 EP EP97105922A patent/EP0807624B1/fr not_active Revoked
- 1992-12-18 WO PCT/US1992/011214 patent/WO1993011755A1/fr not_active Ceased
- 1992-12-18 JP JP51122193A patent/JP4001618B2/ja not_active Expired - Lifetime
- 1992-12-18 AT AT97105922T patent/ATE439341T1/de not_active IP Right Cessation
- 1992-12-18 CA CA002123223A patent/CA2123223C/fr not_active Expired - Lifetime
- 1992-12-18 AT AT93902758T patent/ATE163544T1/de active
- 1992-12-18 DE DE2001199015 patent/DE10199015I2/de active Active
- 1992-12-18 DE DE69233768T patent/DE69233768D1/de not_active Revoked
- 1992-12-18 ES ES93902758T patent/ES2066750T3/es not_active Expired - Lifetime
- 1992-12-18 DE DE0617614T patent/DE617614T1/de active Pending
- 1992-12-18 DE DE69224660T patent/DE69224660C5/de not_active Expired - Lifetime
- 1992-12-18 EP EP93902758A patent/EP0617614B1/fr not_active Expired - Lifetime
- 1992-12-18 DK DK93902758T patent/DK0617614T3/da active
2001
- 2001-04-04 LU LU90752C patent/LU90752I2/fr unknown
- 2001-04-09 NL NL300043C patent/NL300043I2/nl unknown
2007
- 2007-05-07 JP JP2007122307A patent/JP2007254481A/ja active Pending

Also Published As

Publication number	Publication date
EP0807624B1 (fr)	2009-08-12
WO1993011755A1 (fr)	1993-06-24
DE69233768D1 (de)	2009-09-24
AU679171B2 (en)	1997-06-26
EP0617614A1 (fr)	1994-10-05
EP0617614B1 (fr)	1998-03-04
JP2007254481A (ja)	2007-10-04
NL300043I1 (nl)	2001-06-01
JPH08502238A (ja)	1996-03-12
DK0617614T3 (da)	1998-09-28
DE10199015I1 (de)	2001-05-10
EP0807624A2 (fr)	1997-11-19
ATE163544T1 (de)	1998-03-15
DE10199015I2 (de)	2004-01-29
JP4001618B2 (ja)	2007-10-31
AU3421893A (en)	1993-07-19
DE69224660D1 (de)	1998-04-09
EP0807624A3 (fr)	1999-09-29
DE69224660T2 (de)	1998-07-16
CA2123223A1 (fr)	1993-06-24
ATE439341T1 (de)	2009-08-15
DE69224660C5 (de)	2010-06-02
CA2123223C (fr)	2001-10-09
DE617614T1 (de)	1995-06-08
ES2066750T3 (es)	1998-07-01
NL300043I2 (nl)	2001-11-01
ES2066750T1 (es)	1995-03-16

Publication	Publication Date	Title
LU90752I2 (fr)	2001-06-05	Panretin-alitretinoin et ses d-riv-s pharmaceutiquement acceptables
ATE266724T1 (de)	2004-05-15	Multimere der löslichen formen der tnf-rezeptoren,verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
ES2131913T3 (es)	1999-08-01	Derivados de camptotecina.
ATE38672T1 (de)	1988-12-15	7-oxabicycloheptan aminosubstituierte prostaglandinaehnliche verbindungen.
ES2154398T3 (es)	2001-04-01	Piridinas 2,3-sustituidas para el tratamiento de la inflamacion.
UA66750C2 (en)	2004-06-15	Substituted 1-phenylpirazole 3-carboxamides, a method for the preparation thereof and intermediary compounds, pharmaceutical composition having affinity to neurotensin receptors
EA200000391A1 (ru)	2000-12-25	Производные тиенопиримидина и тиенопиридина, полезные в качестве противораковых агентов
DK381583D0 (da)	1983-08-19	Metylsubstituerede 4-metoxypyridin-n-oxyder
TNSN92022A1 (fr)	1993-06-08	Procede de preparation de nouveaux derives de l'indole
NO973017L (no)	1997-08-28	Nye trienoiske retinoid forbindelser og fremgangsmåter
NO951747L (no)	1995-07-05	Fremgangsmåte ved fremstilling av xylitol
SE8307146D0 (sv)	1983-12-23	7-oxabicykloheptan-substituerade aminoprostaglandinanaloger
BG99729A (bg)	1996-01-31	Заместени 6-азаандростенони
CZ282732B6 (cs)	1997-09-17	Substituované 1,2,3,4-tetrahydrocyklopent/b/indoly, 1,2,3,3a,4,8a-hexahydrocyklopent/b/indoly a příbuzné sloučeniny, meziprodukty a způsob jejich přípravy a jejich použití jako léčiv
FR2434167A1 (fr)	1980-03-21	Derives de l'hexahydro-1,2,3,3a,8,8a pyrrolo indole (2,3,-b)
DE69513689D1 (de)	2000-01-05	Trizyclische retinoidverbindungen verfahren zu ihrer herstellung und verwendung
SE8404006L (sv)	1985-02-13	Aspartam-syntes
ES2060944T3 (es)	1994-12-01	Derivados de 2,5,6,7-tetranor-4,8-inter-m-fenileno de pgi2 (prostaglandina i2).
GR900100356A (el)	1991-10-10	Νέα παράγωγα 9α-υδροξυ-3-οξο4,24(25)-στιγμασταδιέν-26-οϊκού οξέος και μέ?οδος για την παρασκευή τους.
ES2061712T3 (es)	1994-12-16	Nuevos derivados sustituidos de 20,21-dinoreburnamenina, su procedimiento de preparacion y los nuevos productos intermedios asi obtenidos, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen.
ES8400401A1 (es)	1983-10-16	"un procedimiento para preparar un 1,4-dialcohilo inferior-3-alcoxicarbonilo inferior-pirrol-2-acetato de alcohilo inferior".
ATE246683T1 (de)	2003-08-15	Indan- oder dihydroindol-derivate
EP0596672A3 (fr)	1994-11-23	Composés contenant des groupes carboxyliques par greffage radicalaire, ainsi que leur préparation.
JPS52136165A (en)	1977-11-14	Purification of pyrrolidine derivatives
JPS5212844A (en)	1977-01-31	Optical fiber system feeding system